R

RELX

Global information analytics and decision tools

Field Account Executive - Federal Government, New Business

Full-TimeUpdated on 10/20/2026
$81.4k - $151.1k
Mid
Bachelor's, Master's, MBA, JD
Washington, DC, USA
HybridMust reside in the Washington, DC metropolitan area (DC, Maryland, or Virginia); attendance at the Washington, DC office two days per week and regular in-person territory meetings are required.
Sales & Account ManagementField Sales
Company Historically Provides H1B Sponsorship

About the job

Requirements
  • A bachelor's degree or equivalent professional experience is required.
  • Proven experience in new business sales, business development, account executive sales, or consultative selling is required.
  • Demonstrated success prospecting for new customers, developing pipeline, and closing new business is required.
  • The ability to independently develop a territory and identify new revenue opportunities is required.
  • Strong discovery, communication, presentation, and negotiation skills are required.
  • Experience managing complex sales cycles involving multiple stakeholders and decision-makers is required.
  • Strong pipeline management, forecasting, and opportunity management skills are required.
  • Proficiency with customer relationship management systems and Microsoft Office applications, including Excel, Word, and PowerPoint, is required.
  • Strong organizational and time management skills and the ability to prioritize opportunities effectively are required.
  • The ability to work collaboratively while maintaining ownership and accountability for individual sales results is required.
  • Must reside within the Washington, DC metropolitan area (DC, Maryland, or Virginia).
Responsibilities
  • Develop and execute a territory strategy focused on acquiring new Federal Government customers and generating new revenue.
  • Identify and prospect into Federal agencies, departments, offices, and other eligible government organizations with new business potential.
  • Build and maintain a healthy sales pipeline through proactive prospecting, referrals, marketing leads, events, and strategic outreach.
  • Establish relationships with key stakeholders, decision-makers, influencers, procurement professionals, and end users within Federal agencies.
  • Conduct discovery to understand customer needs, workflows, challenges, and strategic priorities, and align LexisNexis solutions to those needs.
  • Manage the complete new business sales cycle from initial prospecting and qualification through discovery, demonstration, proposal, negotiation, and close.
  • Develop compelling, solution-oriented proposals with appropriate positioning and pricing for LexisNexis software, content, and services.
  • Navigate complex Federal Government purchasing and procurement processes and develop strategies to advance opportunities.
  • Maintain accurate pipeline management, forecasting, opportunity tracking, and activity within customer relationship management tools.
  • Develop competitive strategies to win business from incumbent providers and overcome customer resistance to change.
  • Collaborate with internal partners, including Solutions Consultants, Marketing, Product, Contracts, and Sales leadership, to advance opportunities and win new business.
  • Represent LexisNexis at customer meetings, industry events, conferences, and trade shows.
  • Conduct regular face-to-face meetings with prospects throughout the assigned territory.
Desired Qualifications
  • Experience selling to Federal Government agencies.
  • Experience navigating Federal Government procurement and contracting processes.
  • Experience selling Legal Technology, Legal Information Services, Software as a Service, Data Analytics, Artificial Intelligence, or Information Solutions.
  • Experience successfully displacing incumbent solutions or developing business within competitive accounts.
  • An advanced degree such as an MBA, Juris Doctor, or related graduate degree.
  • Knowledge of or interest in Artificial Intelligence technologies and AI-enabled business solutions.
  • Experience working in a field sales environment with regular customer-facing interactions.

About the company

RELX is a global provider of information-based analytics and decision tools for professionals across scientific, technical, medical, legal, risk, business, and exhibitions industries. It operates in four segments: Scientific, Technical & Medical; Risk & Business Analytics; Legal; and Exhibitions. Its products combine large datasets, analytics, and decision-support tools to help researchers, healthcare professionals, lawyers, and business leaders make informed choices, improve productivity, and achieve better outcomes. Revenue mainly comes from subscriptions, with additional income from transactional sales and advertising. RELX differentiates itself through its deep data assets, specialized industry knowledge, and multi-segment offerings that span content, analytics, and decision-support services. The company pursues a goal of delivering trusted information and insights while supporting corporate responsibility and alignment with the UN SDGs through its products and partnerships.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

London, United Kingdom

Founded

1894

Get referred to RELX

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • H1 2026 revenue grew 7%; Legal grew 10%; Risk grew 8%.
  • February 24, 2026 Lexis+ with Protégé launched globally, expanding AI workflow adoption.
  • September 3, 2026 Doctrine closes, targeting one million European legal professionals.

What critics are saying

  • Anthropic and Thomson Reuters compressed legal AI pricing after February 2026 market shock.
  • Harvey and Legora court law schools in 2026, training future buyer cohorts elsewhere.
  • Exhibitions face Middle East event uncertainty through 2026, threatening margins and calendar-dependent cash flows.

What makes RELX unique

  • LexisNexis’ 200 billion-document corpus still beats generic legal AI models.
  • September 3, 2026 Doctrine acquisition deepens RELX’s European legal AI workflow moat.
  • H1 2026 subscriptions supplied 62% of revenue, stabilizing cash generation.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Life Insurance
  • Disability Insurance
  • 401(k) Retirement Plan
  • 401(k) Company Match
  • Wellness Program
  • Mental Health Support
  • Family Planning Benefits
  • Health Savings Account/Flexible Spending Account
  • Flexible Work Hours

Company News

Citybiz
Apr 28th, 2026
RELX to Acquire Legaltech Platform Doctrine in European AI Push

RELX Group has entered into an agreement to acquire French legal technology company Doctrine, a move that would expand its... Read More

Business Insider
Mar 1st, 2026
LexisNexis CEO dismisses AI threat as company reports 7% revenue growth

LexisNexis CEO Sean Fitzpatrick has dismissed investor concerns that AI threatens the legal software giant, saying proprietary data gives it a competitive advantage. Shares of parent company Relx fell 14% on 3 February following Anthropic's launch of an AI agent that drafts legal briefs, and are down 17% year-to-date. Fitzpatrick said LexisNexis's database of 200 billion legal documents, including content from Shepard's Citations dating to 1873, cannot be replicated by AI model makers. The company doesn't license its proprietary data to general-purpose AI providers. Relx reported 7% revenue growth for 2025 and 9% increase in adjusted operating profit, driven by customers adopting AI tools. LexisNexis is hiring and hasn't conducted AI-related redundancies.

Yahoo Finance
Feb 22nd, 2026
RELX's LexisNexis launches AI-powered identity management platform for healthcare

LexisNexis Risk Solutions, a wholly owned subsidiary of RELX, has launched a new identity management platform for the healthcare sector. Announced on 19 February, the tool combines identity verification, matching and enrichment capabilities with AI-powered authentication to enhance security throughout patients' healthcare journeys. The platform integrates LexisNexis IDVerse and offers enhanced identity verification, resolution and fraud protection. For healthcare professionals, it accelerates onboarding processes, automates processing and provides digital checks to prevent fraud. RELX is a global information and analytics company serving professional and business customers across scientific, technical, medical, legal and risk management markets.

PR Newswire
Jun 4th, 2025
Elsevier Unveils Rigorous Evaluation Framework To Mitigate Risk In Generative Ai Clinical Decision Support Tools

Clinician-centered framework will be featured in upcoming issue of the Open AccessJournal of the American Medical Informatics Association (JAMIA)Initial evaluations of ClinicalKey AI show high accuracy and usefulness in responses amongst cliniciansNEW YORK, June 4, 2025 /PRNewswire/ -- Elsevier, a global leader in medical information and data analytics, unveiled a groundbreaking evaluation framework for assessing the performance and safety of generative AI-powered clinical reference tools. This innovative approach has been developed for all Elsevier Health generative AI solutions, including ClinicalKey AI, Elsevier's advanced clinical decision support platform, and sets a new standard for responsible AI integration in healthcare. It will be featured in a future issue of the Open Access Journal of the American Medical Informatics Association (JAMIA).The framework, designed with input from clinical subject matter experts across multiple specialties, evaluates AI-generated responses along five critical dimensions: query comprehension, response helpfulness, correctness, completeness, and potential for clinical harm. It serves as a comprehensive assessment to ensure that AI-powered tools not only provide accurate and relevant information but also align with the practical and current needs of healthcare professionals at the point of care.Omry Bigger, President of Clinical Solutions at Elsevier: "This evaluation framework not only supports innovation and advancements to improve patient care but adds an extra layer of review and assessment to ensure physicians are armed with the most accurate information possible. It's a critical step in the implementation of responsible AI for healthcare providers and patients."In a recent evaluation study of ClinicalKey AI, Elsevier worked with a panel of 41-board certified physicians and clinical pharmacists to rigorously test responses generated by the tool for a diverse set of clinical queries. That panel evaluated 426 query-response pairs, and results demonstrated impressive performance, with 94.4% of responses rated as helpful, 95.5% assessed as completely correct, with just 0.47% flagged for potential improvements.Leah Livingston, Director of Generative AI Evaluation for Health Markets at Elsevier, said: "These results reflect not just strong performance, but the real value of bringing clinicians into the evaluation process

PharmiWeb
May 7th, 2025
Elsevier Adds Half A Million Records From Clinicaltrials.Gov To Embase, Enabling A Seamless Search Experience In The World’S Most Comprehensive Biomedical Database

London, 6 May 2025 – Elsevier, a global leader in information and analytics, is announcing the addition of half a million records from ClinicalTrials.gov to its leading biomedical literature database, Embase. The integration will enable researchers to seamlessly view high-quality information on clinical research studies and their results alongside the peer-reviewed literature, in-press publications and conference abstracts already available in Embase. Researchers will be able to conduct more comprehensive evidence and literature searches while having the confidence they will never miss important updates relevant to their drug, therapy, or medical device. Clinical trials data is a vital component of biomedical literature search, helping pharmaceutical and medical device companies stay informed about the latest scientific advancements, regulatory requirements, and competitive insights to support evidence-based decision-making. However, gathering data from multiple sources is currently prone to errors and is time-consuming, such as the duplication of search results, which slows research and regulatory processes. As new therapies and devices are developed and RD organizations seek collaborative partners, they must undertake thorough searches and justifications of evidence